Tag: Anticoagulants
Outcomes May Be Better for Warfarin Users Who Stop Aspirin Use
Quality improvement effort tied to decrease in major bleeding without increase in thrombotic events
Recommendations Issued for Perioperative Antithrombotic Management
Two strong recommendations developed against use of heparin bridging in a-fib, and for continuation of VKA in patients getting pacemaker/ICD
Full-Dose Anticoagulation Beneficial for Critically Ill With COVID-19
However, no significant difference seen in efficacy or safety outcomes for clopidogrel versus no antiplatelet therapy
Formulary Restrictions May Worsen Atrial Fibrillation Outcomes
Risk for adverse health outcomes higher for patients with Medicare Part D plans limiting access to non-vitamin K antagonist oral anticoagulants
Management of Antithrombotics in GI Bleed, Endoscopy Addressed
Guideline addresses management of anticoagulants, antiplatelets during acute gastrointestinal bleeding and in the elective endoscopy setting
NOAC Use Not Tied to ICH in Stroke Patients Treated With Alteplase
Recent use of non-vitamin K antagonist oral anticoagulant not linked to increased risk for intracranial hemorrhage with IV alteplase
DOACs Cut Recurrent VTE in Adults With Cancer-Related Thrombosis
Direct oral anticoagulants reduce recurrent VTE events by 41 percent, with no significant increase in major bleeding, compared to dalteparin
NOACs May Be Better Choice for Patients With A-Fib and DM
Risks for diabetes complications, mortality lower with non-vitamin K antagonist oral anticoagulants versus warfarin
Bleeding Events Up With Full-Dose Thromboprophylaxis in COVID-19
Almost all hospitalized COVID-19 patients with a bleeding event were receiving mechanical ventilation, full-dose anticoagulation
Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19
Adding a P2Y12 inhibitor to a therapeutic dose of heparin does not improve outcomes among non-critically ill patients hospitalized for COVID-19
